The Mycobacterium tuberculosis drugome and its polypharmacological implications

PLoS Computational Biology

Volumn 6, Issue 11, 2010, Pages

  Kinnings, Sarah L ^a,b   Xie, Li ^c   Fung, Kingston H ^d   Jackson, Richard M ^a   Xie, Lei ^c   Bourne, Philip E ^b,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGY;

ANTI TUBERCULARS; CAUSATIVE AGENTS; COMPUTATIONAL APPROACH; DRUG TARGETS; DRUG-TARGET INTERACTIONS; INFECTIOUS DISEASE; INTERACTION NETWORKS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURAL BIOINFORMATICS; SYSTEMS BIOLOGY;

GENOME;

4 HYDROXYTAMOXIFEN; ADENYLATE CYCLASE; ALITRETINOIN; AMANTADINE; CYCLIC AMP; DARUNAVIR; ESTRADIOL; INDINAVIR; LEVOTHYROXINE; LOPINAVIR; METHOTREXATE; NELFINAVIR; PENICILLAMINE; PROPOFOL; PROTEOME; RALOXIFENE; RIFAMPICIN; RITONAVIR; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL DRUGOME; BACTERIAL GENOME; BINDING SITE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MATHEMATICAL MODEL; MOLECULAR MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; STRUCTURAL BIOINFORMATICS; SYSTEMS BIOLOGY; TUBERCULOSIS; BIOLOGICAL MODEL; BIOLOGY; CHEMISTRY; CLUSTER ANALYSIS; COMPUTER SIMULATION; FACTUAL DATABASE; HUMAN; METABOLISM; METHODOLOGY; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; REPRODUCIBILITY;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BINDING SITES; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, FACTUAL; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; TUBERCULOSIS;

EID: 78649661569     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000976     Document Type: Article

References (94)

1. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV (2008) Data completeness- the Achilles heel of drug-target networks. Nat Biotechnol 26: 983-984.
2. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
3. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.
4. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206.
5. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181.
6. Mestres J (2004) Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr Opin Drug Discov Devel 7: 304-313.
7. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321: 263-266.
8. Lamb J (2007) The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54-60.
9. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
10. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M (2008) Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24: i232-240.
11. Nagamine N, Shirakawa T, Minato Y, Torii K, Kobayashi H, et al. (2009) Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. PLoS Comput Biol 5: e1000397.
12. Vina D, Uriarte E, Orallo F, Gonzalez-Diaz H (2009) Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Mol Pharm 6: 825-835.
13. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-906.
14. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
15. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, et al. (2009) Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 5:e1000423.
16. Xie L, Li J, Bourne PE (2009) Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 5: e1000387.
17. Xie L, Wang J, Bourne PE (2007) In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLoS Comput Biol 3: e217.
18. Durrant JD, Amaro RE, Xie L, Urbaniak MD, Ferguson MA, et al. (2010) A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput Biol 6: e1000648.
19. Goulding CW, Apostol M, Anderson DH, Gill HS, Smith CV, et al. (2002) The TB structural genomics consortium: providing a structural foundation for drug discovery. Curr Drug Targets Infect Disord 2: 121-141.
20. Strong M, Sawaya MR, Wang S, Phillips M, Cascio D, et al. (2006) Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103: 8060-8065.
21. Terwilliger TC, Park MS, Waldo GS, Berendzen J, Hung LW, et al. (2003) The TB structural genomics consortium: a resource for Mycobacterium tuberculosis biology. Tuberculosis (Edinb) 83: 223-249.
22. Xie L, Bourne PE (2009) A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics 25: i305-312.
23. Xie L, Bourne PE (2007) A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites. BMC Bioinformatics 8 Suppl 4: S9.
24. Xie L, Bourne PE (2008) Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc Natl Acad Sci U S A 105: 5441-5446.
25. Miller JR, Dunham S, Mochalkin I, Banotai C, Bowman M, et al. (2009) A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci U S A 106: 1737-1742.
26. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, et al. (2007) Structurebased maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25: 71-75.
27. Beste DJ, Hooper T, Stewart G, Bonde B, Avignone-Rossa C, et al. (2007) GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol 8: R89.
28. Jamshidi N, Palsson BO (2007) Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets. BMC Syst Biol 1: 26.
29. Akif M, Akhter Y, Hasnain SE, Mande SC (2006) Crystallization and preliminary X-ray crystallographic studies of Mycobacterium tuberculosis CRP/FNR family transcription regulator. Acta Crystallogr Sect F Struct Biol Cryst Commun 62: 873-875.
30. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, et al. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
31. Lu H, Tonge PJ (2008) Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res 41: 11-20.
32. Linder JU, Schultz A, Schultz JE (2002) Adenylyl cyclase Rv1264 from Mycobacterium tuberculosis has an autoinhibitory N-terminal domain. J Biol Chem 277: 15271-15276.
33. Cooper DM, Crossthwaite AJ (2006) Higher-order organization and regulation of adenylyl cyclases. Trends Pharmacol Sci 27: 426-431.
34. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43: 717-731.
35. Schnell R, Agren D, Schneider G (2008) 1.9 A structure of the signal receiver domain of the putative response regulator NarL from Mycobacterium tuberculosis. Acta Crystallogr Sect F Struct Biol Cryst Commun 64: 1096-1100.
36. Parish T, Smith DA, Kendall S, Casali N, Bancroft GJ, et al. (2003) Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis. Infect Immun 71: 1134-1140.
37. Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH (2004) Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing. J Immunol 173:2660-2668.
38. Lebeis SL, Kalman D (2009) Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions. Cell Host Microbe 5:114-122.
39. Rasko DA, Moreira CG, Li de R, Reading NC, Ritchie JM, et al. (2008) Targeting QseC signaling and virulence for antibiotic development. Science 321:1078-1080.
40. Lee S, Hinz A, Bauerle E, Angermeyer A, Juhaszova K, et al. (2009) Targeting a bacterial stress response to enhance antibiotic action. Proc Natl Acad Sci U S A 106: 14570-14575.
41. Lomovskaya O, Bostian KA (2006) Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem Pharmacol 71:910-918.
42. Hopkins AL (2007) Network pharmacology. Nat Biotechnol 25: 1110-1111.
43. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
44. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7: 460-466.
45. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, et al. (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38-52.
46. Baysarowich J, Koteva K, Hughes DW, Ejim L, Griffiths E, et al. (2008) Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr. Proc Natl Acad Sci U S A 105: 4886-4891.
47. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, et al. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7: 900-907.
48. Ducati RG, Basso LA, Santos DS (2007) Mycobacterial shikimate pathway enzymes as targets for drug design. Curr Drug Targets 8: 423-435.
49. Sulzenbacher G, Canaan S, Bordat Y, Neyrolles O, Stadthagen G, et al. (2006) LppX is a lipoprotein required for the translocation of phthiocerol dimycocerosates to the surface of Mycobacterium tuberculosis. EMBO J 25: 1436-1444.
50. Thakur KG, Joshi AM, Gopal B (2007) Structural and biophysical studies on two promoter recognition domains of the extra-cytoplasmic function sigma factor sigma(C) from Mycobacterium tuberculosis. J Biol Chem 282: 4711-4718.
51. Drumm JE, Mi K, Bilder P, Sun M, Lim J, et al. (2009) Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATPBinding: requirement for establishing chronic persistent infection. PLoS Pathog 5: e1000460.
52. Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, et al. (2004) Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304: 1800-1804.
53. Wolff KA, Nguyen HT, Cartabuke RH, Singh A, Ogwang S, et al. (2009) Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria. Antimicrob Agents Chemother 53: 3515-3519.
54. WHO (2006) Tuberculosis Fact Sheet No.104.
55. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, et al. (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465: 305-310.
56. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, et al. (2010) Chemical genetics of Plasmodium falciparum. Nature 465: 311-315.
57. Gregori-Puigjane E, Mestres J (2008) A ligand-based approach to mining the chemogenomic space of drugs. Comb Chem High Throughput Screen 11:669-676.
58. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV (2009) The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst 5: 1051-1057.
59. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, et al. (2006) Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature 440: 637-643.
60. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL (2000) The large-scale organization of metabolic networks. Nature 407: 651-654.
61. Wagner A, Fell DA (2001) The small world inside large metabolic networks. Proc Biol Sci 268: 1803-1810.
62. Ji HF, Kong DX, Shen L, Chen LL, Ma BG, et al. (2007) Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery. Genome Biol 8: R176.
63. Jeong H, Neda Z, Barabasi AL (2003) Measuring preferential attachment in evolving networks. Europhys Lett 61: 567-572.
64. Newman ME (2001) Clustering and preferential attachment in growing networks. Phys Rev E Stat Nonlin Soft Matter Phys 64: 025102.
65. Eisenberg E, Levanon EY (2003) Preferential attachment in the protein network evolution. Phys Rev Lett 91: 138701.
66. Valas RE, Yang S, Bourne PE (2009) Nothing about protein structure classification makes sense except in the light of evolution. Curr Opin Struct Biol 19: 329-334.
67. Gherardini PF, Ausiello G, Russell RB, Helmer-Citterich M (2010) Modular architecture of nucleotide-binding pockets. Nucleic Acids Res 38: 3809-3816.
68. Brylinski M, Skolnick J (2009) FINDSITE: a threading-based approach to ligand homology modeling. PLoS Comput Biol 5: e1000405.
69. Stockwell GR, Thornton JM (2006) Conformational diversity of ligands bound to proteins. J Mol Biol 356: 928-944.
70. Todd AE, Orengo CA, Thornton JM (2002) Plasticity of enzyme active sites. Trends Biochem Sci 27: 419-426.
71. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.
72. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, et al. (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203-214.
73. Nobeli I, Favia AD, Thornton JM (2009) Protein promiscuity and its implications for biotechnology. Nat Biotechnol 27: 157-167.
74. Chong CR, Sullivan DJ, Jr. (2007) New uses for old drugs. Nature 448: 645-646.
75. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
76. Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, et al. (2003) Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 278: 20851-20859.
77. Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6: 202-210.
78. Pieper U, Eswar N, Webb BM, Eramian D, Kelly L, et al. (2009) MODBASE, a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res 37: D347-354.
79. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, et al. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34: D668-672.
80. Ostergard PRJ (2001) A new algorithm for the maximum-weight clique problem. Nordic J Computing 8: 424-436.
81. Ostergard PRJ (2002) A fast algorithm for the maximum clique problem. Discrete Appl Math 120: 195-205.
82. Ye Y, Godzik A (2003) Flexible structure alignment by chaining aligned fragment pairs allowing twists. Bioinformatics 19 Suppl 2: ii246-255.
83. Becker SA, Feist AM, Mo ML, Hannum G, Palsson BO, et al. (2007) Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox. Nat Protoc 2: 727-738.
84. Zsoldos Z, Reid D, Simon A, Sadjad SB, Johnson AP (2007) eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model 26: 198-212.
85. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genet 38: 500-501.
86. Rickman L, Scott C, Hunt DM, Hutchinson T, Menendez MC, et al. (2005) A member of the cAMP receptor protein family of transcription regulators in Mycobacterium tuberculosis is required for virulence in mice and controls transcription of the rpfA gene coding for a resuscitation promoting factor. Mol Microbiol 56: 1274-1286.
87. He X, Alian A, Stroud R, Ortiz de Montellano PR (2006) Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J Med Chem 49: 6308-6323.
88. Dittrich D, Keller C, Ehlers S, Schultz JE, Sander P (2006) Characterization of a Mycobacterium tuberculosis mutant deficient in pH-sensing adenylate cyclase Rv1264. Int J Med Microbiol 296: 563-566.
89. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
90. Cole ST (1999) Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Lett 452: 7-10.
91. Rengarajan J, Bloom BR, Rubin EJ (2005) Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A 102: 8327-8332.
92. Sassetti CM, Rubin EJ (2003) Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A 100: 12989-12994.
93. Braibant M, Gilot P, Content J (2000) The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev 24: 449-467.
94. Yang Y, Xu S, Zhang M, Jin R, Zhang L, et al. (2006) Purification and characterization of a functionally active Mycobacterium tuberculosis pyrroline-5-carboxylate reductase. Protein Expr Purif 45: 241-248.